Alexion Pharmaceuticals (ALXN) Lowered to "Strong Sell" at BidaskClub
Several other equities analysts have also recently weighed in on the company. Robert W. Baird upgraded Alexion Pharmaceuticals from a "neutral" rating to an "outperform" rating and set a $150.00 price target for the company in a research report on Monday, December 18th.
from Biotech News
0 Comments